A High-Throughput Screening Platform Targeting PDLIM5 for Pulmonary Hypertension

Journal of Biomolecular Screening

Volumn 21, Issue 4, 2016, Pages 333-341

  Cheng, Han ^a   Chen, Tianji ^a   Tor, Merve ^a   Park, Deborah ^a   Zhou, Qiyuan ^a   Huang, Jason B ^a   Khatib, Nour ^a   Rong, Lijun ^a   Zhou, Guofei ^a,b  

^a UNIVERSITY OF ILLINOIS   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

high throughput screening; luciferase reporter assay; PDLIM5; TGF Smad

Indexed keywords

DISULFIRAM; PACLITAXEL; PDLIM5 PROTEIN; PROTEIN; SHORT HAIRPIN RNA; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; ANTIHYPERTENSIVE AGENT; LIM PROTEIN; LUCIFERASE; PDLIM5 PROTEIN, HUMAN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SMAD2 PROTEIN, HUMAN; SMAD3 PROTEIN, HUMAN; SMALL INTERFERING RNA;

ARTICLE; CONTROLLED STUDY; DRUG IDENTIFICATION; EPITHELIUM CELL; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; LENTIVIRINAE; LUNG ALVEOLUS EPITHELIUM CELL; MINK LUNG EPITHELIAL CELL LINE; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; PROTEIN TARGETING; PULMONARY ARTERY SMOOTH MUSCLE CELL; PULMONARY HYPERTENSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; A-549 CELL LINE; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; GENE EXPRESSION; GENE VECTOR; GENETICS; HYPERTENSION, PULMONARY; LUNG; METABOLISM; NEOVISON VISON; PATHOLOGY; PHOSPHORYLATION; REPORTER GENE;

A549 CELLS; ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ANTIHYPERTENSIVE AGENTS; EPITHELIAL CELLS; GENE EXPRESSION; GENES, REPORTER; GENETIC VECTORS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; HYPERTENSION, PULMONARY; LENTIVIRUS; LIM DOMAIN PROTEINS; LUCIFERASES; LUNG; MINK; PACLITAXEL; PHOSPHORYLATION; RNA, SMALL INTERFERING; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 84961253690     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057115625924     Document Type: Article

References (31)

1. Humbert M., Sitbon O., Simonneau G., Treatment of Pulmonary Arterial Hypertension. N. Engl. J. Med. 2004, 351, 1425-1436.
2. McLaughlin V. V., Archer S. L., Badesch D. B., et al. ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: Developed in Collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 2009, 119, 2250-2294.
3. Simonneau G., Gatzoulis M. A., Adatia I., et al. Updated Clinical Classification of Pulmonary Hypertension. J. Am. Coll. Cardiol. 2013, 62 (25 suppl.), D34-D41.
4. Zhou G., Chen T., Raj J. U., MicroRNAs in Pulmonary Arterial Hypertension. Am. J. Respir. Cell Mol. Biol. 2015, 52, 139-151.
5. Chen T., Zhou G., Zhou Q., et al. Loss of MicroRNA-1792 in Smooth Muscle Cells Attenuates Experimental Pulmonary Hypertension via Induction of PDZ and LIM Domain 5. Am. J. Respir. Crit. Care Med. 2015, 191, 678-692.
6. Nakagawa N., Hoshijima M., Oyasu M., et al. ENH, Containing PDZ and LIM Domains, Heart/Skeletal Muscle-Specific Protein, Associates with Cytoskeletal Proteins through the PDZ Domain. Biochem. Biophys. Res. Commun. 2000, 272, 505-512.
7. Ueki N., Seki N., Yano K., et al. Isolation, Tissue Expression, and Chromosomal Assignment of a Human LIM Protein Gene, Showing Homology to Rat Enigma Homologue (ENH). J. Hum. Genet. 1999, 44, 256-260.
8. Krcmery J., Camarata T., Kulisz A., et al. Nucleocytoplasmic Functions of the PDZ-LIM Protein Family: New Insights into Organ Development. Bioessays 2010, 32, 100-108.
9. Te Velthuis A. J. W., Isogai T., Gerrits L., et al. Insights into the Molecular Evolution of the PDZ/LIM Family and Identification of a Novel Conserved Protein Motif. PLoS ONE 2007, 2, e189.
10. Cheng H., Kimura K., Peter A. K., et al. Loss of Enigma Homolog Protein Results in Dilated Cardiomyopathy. Circ. Res. 2010, 107, 348-356.
11. Abe M., Harpel J. G., Metz C. N., et al. An Assay for Transforming Growth Factor-Beta Using Cells Transfected with a Plasminogen Activator Inhibitor-1 Promoter-Luciferase Construct. Anal. Biochem. 1994, 216, 276-284.
12. Zhou Q., Pardo A., Konigshoff M., et al. Role of von Hippel-Lindau Protein in Fibroblast Proliferation and Fibrosis. Faseb. J. 2011, 25, 3032-3044.
13. Shaikh D., Zhou Q., Chen T., et al. cAMP-Dependent Protein Kinase Is Essential for Hypoxia-Mediated Epithelial-Mesenchymal Transition, Migration, and Invasion in Lung Cancer Cells. Cell Signal. 2012, 24, 2396-2406.
14. Zhou Q., Chen T., Bozkanat M., et al. Intratracheal Instillation of High Dose Adenoviral Vectors Is Sufficient to Induce Lung Injury and Fibrosis in Mice. PLoS ONE 2014, 9, e116142.
15. Schneider C. A., Asband W. S., Eliceiri K. W., et al. NIH Image to ImageJ: 25 Years of Image Analysis. Nat. Methods 2012, 9, 671-675.
16. Collins T. J., ImageJ for Microscopy. Biotechniques 2007, 43 (1 suppl), 25-30.
17. Zhang Q., Liu Z., Mi Z., et al. High-Throughput Assay to Identify Inhibitors of Vpu-Mediated Down-Regulation of Cell Surface BST-2. Antiviral Res. 2011, 91, 321-329.
18. Zhang J. H., Chung T. D., Oldenburg K. R., A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J. Biomol. Screen. 1999, 4, 67-73.
19. Yan Y., Tsukamoto O., Nakano A., et al. Augmented AMPK Activity Inhibits Cell Migration by Phosphorylating the Novel Substrate Pdlim5. Nat. Commun. 2015, 6, 6137.
20. Savai R., Al-Tamari H. M., Sedding D., et al. Pro-Proliferative and Inflammatory Signaling Converge on FoxO1 Transcription Factor in Pulmonary Hypertension. Nat. Med. 2014, 20, 1289-1300.
21. Akhurst R. J., Hata A., Targeting the TGFbeta Signalling Pathway in Disease. Nat. Rev. Drug Discov. 2012, 11, 790-811.
22. Yingling J. M., Blanchard K. L., Sawyer J. S., Development of TGF-beta Signalling Inhibitors for Cancer Therapy. Nat. Rev. Drug Discov. 2004, 3, 1011-1022.
23. Massague J., TGFbeta Signalling in Context. Nat. Rev. Mol. Cell Biol. 2012, 13, 616-630.
24. Nagaraj N. S., Datta P. K., Targeting the Transforming Growth Factor-beta Signaling Pathway in Human Cancer. Expert Opin. Investig. Drugs 2010, 19, 77-91.
25. Chambers A. F., Groom A. C., MacDonald I. C., Dissemination and Growth of Cancer Cells in Metastatic Sites. Nat. Rev. Cancer 2002, 2, 563-572.
26. MacDonald I. C., Groom A. C., Chambers A. F., Cancer Spread and Micrometastasis Development: Quantitative Approaches for In Vivo Models. BioEssays 2002, 24, 885-893.
27. Levy L., Hill C. S., Alterations in Components of the TGF-beta Superfamily Signaling Pathways in Human Cancer. Cytokine Growth Factor Rev. 2006, 17, 41-58.
28. Kurooka H., Yokota Y., Nucleo-Cytoplasmic Shuttling of Id2, a Negative Regulator of Basic Helix-Loop-Helix Transcription Factors. J. Biol. Chem. 2005, 280, 4313-4320.
29. Lasorella A., Iavarone A., The Protein ENH Is a Cytoplasmic Sequestration Factor for Id2 in Normal and Tumor Cells from the Nervous System. Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 4976-4981.
30. Kuroda S., Tokunaga C., Kiyohara Y., et al. Protein-Protein Interaction of Zinc Finger LIM Domains with Protein Kinase C. J. Biol. Chem. 1996, 271, 31029-31032.
31. Georgiadis M. S., Russell E. K., Gazdar A. F., et al. Paclitaxel Cytotoxicity against Human Lung Cancer Cell Lines Increases with Prolonged Exposure Durations. Clin. Cancer Res. 1997, 3, 449-454.